Peregrine Capital Management LLC reduced its holdings in shares of Bruker Corporation (NASDAQ:BRKR – Free Report) by 8.8% in the 1st quarter, HoldingsChannel reports. The fund owned 126,630 shares of the medical research company’s stock after selling 12,174 shares during the quarter. Peregrine Capital Management LLC’s holdings in Bruker were worth $4,574,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the business. Los Angeles Capital Management LLC acquired a new stake in shares of Bruker during the 4th quarter worth about $26,000. Allworth Financial LP lifted its stake in Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares during the last quarter. Parallel Advisors LLC boosted its holdings in Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares in the last quarter. Summit Securities Group LLC purchased a new position in Bruker in the fourth quarter valued at approximately $50,000. Finally, Covestor Ltd increased its stake in Bruker by 304.6% in the fourth quarter. Covestor Ltd now owns 1,416 shares of the medical research company’s stock valued at $67,000 after purchasing an additional 1,066 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.
Insider Buying and Selling
In other news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the completion of the sale, the vice president owned 128,443 shares in the company, valued at approximately $5,124,875.70. This trade represents a 1.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 27.20% of the company’s stock.
Bruker Trading Up 0.8%
Bruker (NASDAQ:BRKR – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.23 by $0.08. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The business had revenue of $823.40 million during the quarter, compared to analysts’ expectations of $795.62 million. During the same quarter in the prior year, the business earned $0.47 earnings per share. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities analysts forecast that Bruker Corporation will post 2.12 EPS for the current year.
Bruker Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd will be given a dividend of $0.05 per share. The ex-dividend date is Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Bruker’s dividend payout ratio is presently -83.33%.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on BRKR shares. TD Cowen boosted their price target on shares of Bruker from $43.00 to $45.00 and gave the company a “hold” rating in a research report on Thursday, May 7th. Stifel Nicolaus set a $45.00 target price on Bruker in a report on Friday, May 8th. Wolfe Research started coverage on Bruker in a research note on Monday, June 1st. They set a “peer perform” rating on the stock. Weiss Ratings raised Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. Finally, Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Bruker presently has a consensus rating of “Hold” and an average price target of $54.54.
Get Our Latest Research Report on BRKR
About Bruker
Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.
Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.
In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.
Read More
- Five stocks we like better than Bruker
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR – Free Report).
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.
